HIV vaccines and methods of using
AssigneeGilead Sciences, Inc.
InventorsJiani Li, Xinan Liu, Azure T. Makadzange, Stephen R. Martin, Hesham Shehata, Evguenia Svarovskaia
Life of this patent
Estimating the term…
Abstract
Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.
Claims12
A fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs:
- 82-89, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:
- 82-89, wherein the full-length of the fusion polypeptide comprises at least 350 amino acids and up to 385 amino acids, and wherein the fusion polypeptide is capable of inducing, promoting or stimulating an immune response in a human.
Dependencies are inferred from the claim text.